期刊
PAIN
卷 149, 期 2, 页码 263-272出版社
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1016/j.pain.2010.02.010
关键词
Cancer pain; Protease activated receptor 2; PAR2; Protease; Trypsin
资金
- NIH/NIDCR [R21 DE018561]
- NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R21DE018561] Funding Source: NIH RePORTER
Mediators involved in the generation of pain in patients with cancer are poorly understood. Using a combined molecular, pharmacologic, behavioral, and genetic approach, we have identified a novel mechanism of cancer-dependent allodynia induced by protease-activated receptor 2 (PAR2). Here we show that human head and neck carcinoma cells have increased levels of proteolytic activity compared to normal human cell controls. Supernatant from human carcinoma cells, but not controls, caused marked and prolonged mechanical allodynia in mice, when administered into the hindpaw. This nociceptive effect was abolished by serine protease inhibition, diminished by mast cell depletion and absent in PAR2-deficient mice. In addition, non-contact co-culture of trigeminal ganglion neurons with human head and neck carcinoma cells increased the proportion of neurons that exhibited PAR2-immunoreactivity. Our results point to a direct role for serine proteases and their receptor in the pathogenesis of cancer pain. This previously unrecognized cancer pain pathway has important therapeutic implications wherein serine protease inhibitors and PAR2 antagonists may be useful for the treatment of cancer pain. (C) 2010 International Association for the Study of Pain. Published by Elsevier B. V. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据